A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint

被引:0
作者
Qing, Yun [1 ,2 ]
Thall, Peter F. [1 ]
Yuan, Ying [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[2] Univ Texas Hlth Sci Ctr Houston, Dept Biostat & Data Sci, Houston, TX 77030 USA
关键词
Bayesian adaptive design; futility monitoring; go; no-go decision; interim analysis; OPTIMAL 2-STAGE DESIGNS; CLINICAL-TRIALS; SURVIVAL; SAMPLE;
D O I
10.1002/pst.2256
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A robust Bayesian design is presented for a single-arm phase II trial with an early stopping rule to monitor a time to event endpoint. The assumed model is a piecewise exponential distribution with non-informative gamma priors on the hazard parameters in subintervals of a fixed follow up interval. As an additional comparator, we also define and evaluate a version of the design based on an assumed Weibull distribution. Except for the assumed models, the piecewise exponential and Weibull model based designs are identical to an established design that assumes an exponential event time distribution with an inverse gamma prior on the mean event time. The three designs are compared by simulation under several log-logistic and Weibull distributions having different shape parameters, and for different monitoring schedules. The simulations show that, compared to the exponential inverse gamma model based design, the piecewise exponential design has substantially better performance, with much higher probabilities of correctly stopping the trial early, and shorter and less variable trial duration, when the assumed median event time is unacceptably low. Compared to the Weibull model based design, the piecewise exponential design does a much better job of maintaining small incorrect stopping probabilities in cases where the true median survival time is desirably large.
引用
收藏
页码:34 / 44
页数:11
相关论文
共 50 条
  • [41] Sample size determination for time-to-event endpoints in randomized selection trials with generalized exponential distribution
    Akbar, Muhammad Hamza
    Ali, Sajid
    Shah, Ismail
    Alqifari, Hana N.
    [J]. HELIYON, 2024, 10 (05)
  • [42] Trial Design with Win Statistics for Multiple Time-to-Event Endpoints with Hierarchy
    Barnhart, Huiman X.
    Lokhnygina, Yuliya
    Matsouaka, Roland A.
    Rockhold, Frank W.
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2025, 17 (02): : 197 - 210
  • [43] TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades
    Takeda, Kentaro
    Xia, Qing
    Liu, Shufang
    Rong, Alan
    [J]. PHARMACEUTICAL STATISTICS, 2022, 21 (02) : 496 - 506
  • [44] Sample size considerations for single-arm clinical trials with time-to-event endpoint using the gamma distribution
    Dai, Junqiang
    He, Jianghua
    Phadnis, Milind A.
    [J]. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2024, 41
  • [45] Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials
    Renfro, Lindsay A.
    Shi, Qian
    Sargent, Daniel J.
    Carlin, Bradley P.
    [J]. STATISTICS IN MEDICINE, 2012, 31 (08) : 743 - 761
  • [46] Joint modelling of longitudinal response and time-to-event data using conditional distributions: a Bayesian perspective
    Dutta, Srimanti
    Molenberghs, Geert
    Chakraborty, Arindom
    [J]. JOURNAL OF APPLIED STATISTICS, 2022, 49 (09) : 2228 - 2245
  • [47] Confirmatory adaptive group sequential designs for single-arm phase II studies with multiple time-to-event endpoints
    Danzer, Moritz Fabian
    Terzer, Tobias
    Berthold, Frank
    Faldum, Andreas
    Schmidt, Rene
    [J]. BIOMETRICAL JOURNAL, 2022, 64 (02) : 312 - 342
  • [48] Comparison of an ordinal endpoint to time-to-event, longitudinal, and binary endpoints for use in evaluating treatments for severe influenza requiring hospitalization
    Peterson, Ross L.
    Vock, David M.
    Babiker, Abdel
    Powers, John H., III
    Hunsberger, Sally
    Angus, Brian
    Paez, Armando
    Neaton, James D.
    [J]. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2019, 15
  • [49] Time-to-event calibration-free odds design: A robust efficient design for phase I trials with late-onset outcomes
    Jin, Huaqing
    Yin, Guosheng
    [J]. PHARMACEUTICAL STATISTICS, 2023, 22 (05) : 773 - 783
  • [50] DODII: Bayesian Dose Optimization Design for Randomized Phase II Trials
    Yu, Ziji
    Wang, Yanzhao
    Lin, Jianchang
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2024, 16 (03): : 294 - 304